Hepatitis B and C Screening for Immigration Medical Examinations
Screen all immigration applicants with hepatitis B surface antigen (HBsAg) testing for hepatitis B and anti-HCV antibody testing followed by confirmatory HCV RNA PCR for hepatitis C. 1, 2
Hepatitis B Screening Approach
Who to Screen
- All individuals born in countries with HBsAg prevalence ≥2% should be screened regardless of vaccination history in their country of origin 1
- This includes most of Asia, Africa, Pacific Islands, and parts of South America 1
- The rationale is straightforward: immigration populations from endemic regions have substantially elevated HBV prevalence (9-14% in some migrant groups) 3
Testing Method
- Initial test: HBsAg (FDA-approved test) 1
- Confirmatory testing for initially reactive results 1
- If HBsAg negative, consider adding total anti-HBc to identify past infection and determine vaccination needs 3
- Studies show 47% of HBsAg-negative migrants have anti-HBc positivity, indicating prior exposure 3
Hepatitis C Screening Approach
Who to Screen
- Universal screening for all adults aged 18-79 years per current USPSTF guidelines 2
- This applies to immigration medical examinations as immigrants fall within this age range
- For those under 18 or over 79 with high-risk factors (injection drug use history), consider screening 2
Testing Method
- Initial test: Anti-HCV antibody 2
- Confirmatory test: HCV RNA by PCR for all anti-HCV positive results 2
- This two-step approach is critical because antibody positivity alone doesn't distinguish active from cleared infection
Practical Implementation
High-Yield Populations
Research demonstrates screening coverage during immigration medical examinations achieves:
- 95.8% for hepatitis B 4
- High detection rates with 3-3.3% HBsAg positivity and 1-3.3% HCV positivity in migrant populations 3, 5
Geographic Risk Stratification for HBV
While universal HBV screening is recommended for immigrants from endemic areas, prevalence varies:
- Sub-Saharan Africa: 14% HBsAg positivity 3
- Eastern Europe: 6% 3
- South Asia (India-Pakistan area): 3% 3
- Northern Africa: 2% 3
Geographic Risk for HCV
Critical Pitfalls to Avoid
Do not skip confirmatory testing. Initial reactive HBsAg or anti-HCV results require confirmation before diagnosis 1, 2. For HCV specifically, anti-HCV positivity without RNA confirmation may represent cleared infection rather than active disease requiring treatment.
Do not assume vaccination history from endemic countries is reliable. Screen regardless of reported vaccination status 1. Many countries have variable vaccine coverage and documentation.
Do not perform one-time screening only for high-risk individuals. Those with ongoing risk factors (injection drug use, high-risk sexual behavior) require periodic rescreening 1, 2.
Linkage to Care
The screening is only valuable if positive results lead to treatment:
- HBsAg-positive individuals need hepatology referral for treatment evaluation 1
- HCV RNA-positive individuals should be referred for direct-acting antiviral therapy (8-12 week oral regimens) 2
- Studies show linkage to care remains challenging, with only 36-50% of positive migrants successfully referred to hepatology 5
Cost-Effectiveness Evidence
Combined HBV/HCV screening in migrant populations is highly cost-effective, with incremental cost-effectiveness ratios of €4,962-9,375 per QALY gained, well below standard thresholds 6. This supports universal screening in immigration medical examinations from both clinical and economic perspectives.